

CLASSIFICATION: UNCLASSIFIED/
ROUTINE
R 031702Z APR 26 MID180038693049U
FM CNO WASHINGTON DC
TO NAVADMIN
INFO CNO WASHINGTON DC
BT
UNCLAS

NAVADMIN 078/26

MSGID/NAVADMIN/CNO WASHINGTON DC/N9/APR//

SUBJ/FIELDING OF NAVY ADVANCED ANTICONVULSANT SYSTEM (AAS) FOR NERVE AGENT TREATMENT//

REF/A/DOC/OPNAV/24APR25//
REF/B/DOC/JRO/24AUG07//
REF/C/DOC/NWDC/16APR19//
REF/D/DOC/OPNAV/2APR24//
REF/E/DOC/BUMED/17APR23//

NARR/ REF A IS OPNAVINST 3400.10J, CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR DEFENSE REQUIREMENTS SUPPORTING OPERATIONAL READINESS.

REF B IS ADVANCED NERVE AGENT COUNTERMEASURES CAPABILITY DEVELOPMENT DOCUMENT.

REF C IS NTRP 4-02.22, MULTI-SERVICE TACTICS, TECHNIQUES, AND PROCEDURES FOR TREATMENT OF CHEMICAL WARFARE AGENT CASUALTIES AND CONVENTIONAL MILITARY CHEMICAL INJURIES.

REF D IS OPNAVINST 6700.3, MANAGEMENT OF MEDICAL AND DENTAL ASSEMBLAGE MATERIEL FOR NAVAL EXPEDITIONARY HEALTH SERVICE SUPPORT.

REF E IS MANUAL OF THE MEDICAL DEPARTMENT - ARTICLE 21-5.

POC/DR LILIYA SILAYEVA/OPNAV ARLINGTON VA/(571)256-8033/EMAIL:
LILIYA.P.SILAYEVA.CTR@US.NAVY.MIL//
POC/LCDR SAMSON OYELAMI/FLEET FORCES COMMAND NORFOLK VA/
(757)836-0107/EMAIL: SAMSON.F.OYELAMI.MIL@US.NAVY.MIL//

RMKS/1. PER REFERENCES (A) THROUGH (E), THIS MESSAGE OUTLINES THE PROCESS FOR REQUISITIONING THE ADVANCED ANTICONVULSANT SYSTEM (AAS) FOR THE FLEET AND EXPEDITIONARY FORCE TO REPLACE THE LEGACY CONVULSANT ANTIDOTE FOR NERVE AGENT (CANA).

2. AS THE EXECUTIVE AGENT (EA) FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR DEFENSE (CBRND), OPNAV N96 COORDINATES THE INITIAL FIELDING OF CBRN MEDICAL COUNTERMEASURES THROUGH THE JOINT PROGRAM EXECUTIVE OFFICE FOR CBRND (JPEO-CBRND) AT NO COST TO THE NAVY, PER REFERENCE (A). AAS, DESIGNED TO REPLACE CANA, IS A SINGLE-CHAMBER AUTOINJECTOR THAT DELIVERS 10 MG OF MIDAZOLAM FOR THE TREATMENT OF SEIZURES CAUSED BY EXPOSURE TO NERVE AGENTS, PER REFERENCE (B). IN CONDITIONS DICTATED BY REFERENCE (C), UNITS WILL ISSUE EACH SERVICE MEMBER ONE AAS, WHICH THEY WILL CARRY TO BE ADMINISTERED BY BUDDY-AID FOR USE IN THE PREVENTION AND TREATMENT OF SEIZURES FROM NERVE AGENT POISONING.

3. ADMINISTRATIVE ACTIONS. THE FOLLOWING ADMINISTRATIVE ACTIONS ARE REQUIRED IN SUPPORT OF THE TRANSITION FROM CANA TO AAS:

A. ADDITION OF AAS TO THE APPROVED AMAL: PER REFERENCE (D), ENSURE AAS IS CAPTURED IN EACH UNIT'S TABLES OF ALLOWANCE (TOA) AND CROSS-REFERENCED TO A COMPLETE ASSEMBLAGE LIST MAINTAINED WITHIN THE NAVAL ASSEMBLAGE INFORMATION LOGISTICS SYSTEM (NAILS), MEDICAL ASSEMBLAGE METADATA SUITE (MAMS), OR THE MEDICAL CONTINGENCY REQUIREMENTS WORKFLOW (MCRW) MANAGED BY DEFENSE LOGISTICS AGENCY (DLA) - FUNCTIONAL EXECUTIVE AGENT MEDICAL SUPPORT. THE NSN FOR THIS ISSUANCE OF NAVY AAS IS 6505-31-019-3788/NDC 71053-595-01 (480 EA). FUTURE REQUISITIONS FULFILLED THROUGH DLA-TROOP SUPPORT (TS) (AFTER THE PRODUCT HAS ENTERED THE SUSTAINMENT PHASE - I.E., AT COST TO NAVY) WILL HAVE THE FOLLOWING NSNS: 6505-31-018-8242/ NDC 71053-0595-02 U/I (40 BOX) AND 6505-31-019-0519/ NDC 71053-0595-03 U/I (1 EA).

B. COMPLIANCE WITH REGULATORY ACCOUNTABILITY FOR SCHEDULE III, IV, AND V CONTROLLED SUBSTANCES: PER REFERENCE (E), ENSURE APPROPRIATE HANDLING, STORAGE, INITIAL INVENTORY, AND REGULAR AUDITS OF INVENTORY OF AAS.

C. USFF IS FORMULATING DISPOSAL REQUIREMENTS AND PROCEDURES FOR LEGACY CANA INVENTORY, WHICH OPNAV WILL PROMULGATE VIA SEPARATE MESSAGE.

4. REQUISITION OF AAS: UNITS WILL COORDINATE WITH OPNAV N96 AND USFF MEDLOG POCs FOR REQUISITION APPROVAL BEFORE ROUTING TO DLA-TS FOR FINAL EXECUTION AND RELEASE FOR SHIPMENT. ADDITIONAL QUANTITIES REQUIRED MUST BE COORDINATED THROUGH OPNAV N96 UNTIL AAS BECOMES AVAILABLE FOR PURCHASE THROUGH DLA-TS LATER IN CY26.

5. RELEASED BY RADM MARK D. BEHNING, ACTING DEPUTY CHIEF OF NAVAL OPERATIONS, WARFIGHTING REQUIREMENTS AND CAPABILITIES (N9).//

BT

#0001

NNNN

CLASSIFICATION: UNCLASSIFIED/